therapy system News
-
Brain Initiative Investigator Conference
December 19, 2016: In collaboration with researchers at the University of Maryland, WMP presented a poster at the Brain Initiative Investigator Conference in North Bethesda, MD, entitled “Wireless Current Detection Using a Spin-Transfer Nano-Oscillator by Near-Field Induction.” This class of particles shows strong promise as a neuromodulator and brain-readout particle that can be ...
-
Lungpacer Medical, Inc. Announces Completion of RESCUE 2 European Clinical Study
Lungpacer Medical, Inc., announced the completion of enrollment and follow up in its RESCUE 2 European CE Mark randomized clinical trial. This is a randomized study that enrolled a total of 110 subjects in France and Germany and evaluated the safety and effectiveness of the Lungpacer Therapy System in subjects who were expected to have ventilator-induced diaphragm dysfunction (VIDD) and be ...
-
medPhoton’s ImagingRing technology in clinical use at Maastro Clinic
medPhoton’s ceiling mounted ImagingRing integrated to the MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning at Zuid-Oost Nederland Protonen Therapie Centrum, (ZON-PTC) at the MAASTRO Clinic in Maastricht, the Netherlands. Patient treatment has begun on February 8, 2019 as a result of a close collaboration between Mevion, Maastro Clinic and medPhoton. “Proton ...
-
Shonan Kamakura Advanced Medical Center Begins Treatment with Hitachi`s First Dedicated Compact Proton Therapy System
Hitachi, Ltd. (TSE: 6501, ”Hitachi”) today announced that “Shonan Kamakura Advanced Medical Center” at Shonan Kamakura General Hospital of Tokushukai Medical Group, where Hitachi's compact proton therapy system (hereafter, “the system”) has been installed, has commenced treatment with the system on 31 January 2022. This is the first order for Hitachi’s ...
-
Mevion Selected to Equip Compact Proton Therapy Center in Kansas City
Mevion Medical Systems is pleased to announce it has signed a contract with Kansas City Urology Care (KCUC) for the purchase of a MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning technology. Proton therapy is a precise form of radiation therapy that can reduce the amount of unnecessary radiation exposure to healthy tissue, which has the potential to reduce side ...
-
CUREosity at MEDICA 2021
Experience our innovative virtual reality (VR) therapy system CUREO live at the MEDICA, November 15-18, 2021. We will be at the NRW booth in hall 3, booth number C80. We will also give presentations and talk about the advantages that come with virtual reality-based therapy Come by and check out live demonstrations of our smart therapy system that supports cognitive and sensorimotor ...
-
Mevion Selected to Equip Proton Therapy Center at Tongji Hospital in China
Mevion Medical Systems today announced it has been selected by Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology to equip their new proton therapy center with a MEVION S250i Proton Therapy System® in Wuhan, China. The system at Tongji Hospital will feature Mevion’s industry leading HYPERSCAN® Pencil Beam Scanning (PBS) technology, ...
-
Third Pole Therapeutics to Present at Biotech Showcase 2020
Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, announced today its Chief Executive Officer Bill Athenson will present at Biotech Showcase 2020 to be held January 13-15, 2020 at the Hilton San Francisco Union Square. During the presentation Mr. Athenson will discuss Third Pole’s strategy for its ...
-
Mevion Selected to Equip New Proton Therapy and Research Center in San Antonio
Mevion Medical Systems and Proton International announce the selection of the MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS) to equip the UT Health San Antonio Proton Therapy and Research Center. It will be the first proton therapy system in San Antonio and South Texas to provide this advanced alternative to conventional radiation therapy for cancer. Proton ...
-
BIONIK Laboratories to Participate at MEDICA, a Leading International Trade Show for the Medical Industry
TORONTO & BOSTON--(BUSINESS WIRE)-- BIONIK Laboratories Corp. (OTCQB: BNKL) (“BIONIK” or the “Company”), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced its participation in the MEDICA Trade Show in Dusseldorf, Germany from November ...
By Bionik
-
Ackerman Cancer Center Celebrates 2,000 Patients Treated with Proton Therapy
Ackerman Cancer Center (ACC), the world’s first and only physician-owned proton therapy center, has reached a significant milestone in cancer care with the treatment of their 2,000th proton therapy patient. The Mevion-equipped center treated its first proton therapy patient in April of 2015 and reached its 1,000th patient milestone in October of 2018. “Congratulations to the ...
-
BioCardia Establishes New Manufacturing Facility to Enable Its Cell Therapy Product Candidates
BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that it has entered into a long-term lease for a new facility in Sunnyvale, California. This facility is being built out to support the manufacturing of BioCardia’s cell and device products and product candidates across the ...
-
Virica Biotech to be Showcased in Xtalks Webinar: Process Intensification in AAV Gene Therapy
Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, will be featured in a live webinar to be held on Monday, November 14, 2022, at 2:30pm EST. This webinar will focus on process intensification in the manufacturing of adeno associated virus (AAV) vectors. AAV vectors are critical to gene therapy development. These vectors are the delivery ...
-
Lungpacer Medical, Inc. Announces FDA Approval of Emergency Use Authorization of the Lungpacer Diaphragm Pacing Therapy System to Help Address COVID-19 Pandemic
Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced today that the FDA has approved the Emergency Use Authorization for the use of the Lungpacer Diaphragm Pacing Therapy System (DPTS) to assist in weaning patients determined by their healthcare provider to be at high risk of weaning failure. According to the FDA ...
-
Update of the virtual reality therapy system CUREO for more efficient and therapist-relieving therapy
With the update 2.0 of the virtual reality therapy system CUREO® of the med-tech company CUREosity from Düsseldorf, therapy is optimized with intuitive, digital and efficient tools. Based on user analysis and evaluation of feedback from clinics, therapists and patients, we have further developed our system to relieve therapists. The update has been officially available since January 31. ...
-
Sommetrics Engages Key West Investments to Raise Additional Capital, Prepares for Commercialization of Sleep Apnea Therapy
SAN DIEGO, Calif. — October 24, 2017 — Sommetrics, a company providing products and services to improve sleep quality, today announced that it has engaged Key West Investments to help raise additional capital. This capital will support the company’s development and commercialization of products to treat disorders of the upper airway such as obstructive sleep apnea and chronic ...
By Sommetrics
-
BIONIK Laboratories to Participate at the American Physical Therapy Association Conference
BOSTON--(BUSINESS WIRE)-- BIONIK Laboratories Corp. (OTCQB: BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced its participation in the American Physical Therapy Association (APTA) Conference in San Antonio, Texas from February ...
By Bionik
-
BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure
BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CardiAMP® Cell Therapy System for the treatment of heart failure. It is believed to be the first cardiac cell therapy to ...
-
AVEO Oncology Announces Addition of FOTIVDA® (tivozanib) into National Comprehensive Cancer Network Clinical Practice Guidelines
AVEO Oncology (Nasdaq: AVEO) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include FOTIVDA® (tivozanib) as a recommended regimen for subsequent therapy. The subsequent therapy category follows the first-line treatment regimen recommendations for patients with clear cell histology renal cell carcinoma (ccRCC). On March 10, ...
-
SQZ Biotechnologies Announces Integrated Point-ofCare Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process
WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ) announced today that the company’s rst generation, integrated point-of-care (POC) cell therapy manufacturing system demonstrated superior process performance and comparable or improved product specications relative to current clean room-based processes used in clinical development. The non-clinical studies showed that the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you